Published in Ann Plast Surg on May 01, 2001
Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol (2008) 1.03
Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg (2005) 0.90
Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg (2003) 0.88
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst (1993) 2.57
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Mycosis fungoides palmaris et plantaris. Arch Dermatol (1995) 2.25
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol (1996) 2.03
The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer (2001) 1.99
Smooth versus textured expander implants: a double-blind study of capsule quality and discomfort in simultaneous bilateral breast reconstruction patients. Ann Plast Surg (1994) 1.98
Aggressive digital papillary adenocarcinoma: a case report and review of the literature. Am J Dermatopathol (2001) 1.97
Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc (1999) 1.96
Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med (1991) 1.95
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am (1997) 1.80
Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
A retrospective study of changes in physical symptoms and body image after reduction mammaplasty. Plast Reconstr Surg (1999) 1.73
Extraadrenal myelolipoma: MR imaging findings. AJR Am J Roentgenol (1998) 1.73
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res (1994) 1.72
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol (2001) 1.70
Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol (1999) 1.69
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann Surg Oncol (2000) 1.58
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57
Action spectrum for retinal injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol (1982) 1.56
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood (1994) 1.53
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med (1977) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Characterization of a cDNA clone encoding human filaggrin and localization of the gene to chromosome region 1q21. Proc Natl Acad Sci U S A (1989) 1.46
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res (1996) 1.44
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol (1994) 1.44
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood (1990) 1.44
IL-12 synthesis by human Langerhans cells. J Immunol (1996) 1.43
Ultraviolet-assisted punch biopsy mapping for lentigo maligna melanoma. Ann Plast Surg (2001) 1.41
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol (1999) 1.40
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol (1993) 1.39
Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest (1995) 1.39
Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res (1994) 1.38
Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol (1998) 1.37
Observations on Cogan's microcystic dystrophy of the corneal epithelium. Trans Am Ophthalmol Soc (1965) 1.35
The nature of retinal radiation damage: dependence on wavelength, power level and exposure time. Vision Res (1980) 1.33
Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet (2004) 1.32
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med (2006) 1.29
The fate of suctioned and surgically removed fat after reimplantation for soft-tissue augmentation: a volumetric and histologic study in the rabbit. Plast Reconstr Surg (1993) 1.27
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood (2000) 1.26
Proliferation, differentiation, and cytogenetics of chronic leukemic B lymphocytes cultured with mitomycin-treated normal cells. Blood (1981) 1.25
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol (1997) 1.23
Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol (1993) 1.23
Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol (1994) 1.22
Basic mechanisms underlying the production of photochemical lesions in the mammalian retina. Curr Eye Res (1984) 1.21
Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood (1999) 1.20